The Beginning of the End of Clinical Trials As We Know Them?
COVID-19 will not only leave a long legacy on public health, but it may also force companies that have been lagging behind the disruption curve to adopt technologies and processes that will make clinical trials more efficient.
Our own contributor, Moe Alsumidae, recently
COVID-19 will not only leave a long legacy on public health (and a plethora of other institutions) as we know it, but will it also force companies that have been lagging behind the disruption curve to adopt technologies and processes that will make clinical trials more efficient?
Moe’s was not the only rallying cry. From
Just check our
Most of those services, software, or toolkits were from providers that, not surprisingly, have a remote, centralized, or patient-centric aspect. Decentralized and hybrid trials had been the words of day coming into 2020; the pandemic is bringing virtual and remote to new heights. If you thought remote monitoring of a clinical trial was too much change for your organization, how did the complete inability to get into a quarantined site to verify source data go?
But, it’s only early April. We are all still scrambling to maintain some semblance of a work life, let alone a personal or family life for the next maybe 30 days. Applied Clinical Trials isn’t your news go-to, we know that. We are the ones that provide practical, hands-on solutions to the current clinical trials industry.
Suffice to say, we are already reshaping our future content to bring the lessons learned from COVID-19 to bear on this next phase of clinical trials. Stay healthy.
Lisa Henderson is Editor-in-Chief of Applied Clinical Trials. She can be reached at
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.